Séverine Sarp

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Amir Sonnenblick, Dominique Agbor‐Tarh, Ian Bradbury et al. · Journal of Clinical Oncology · 2017 · 167 citations

Medicine, Oncology, Pharmacotherapy +17

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE

Stephen Johnston, Roberto Hegg, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2017 · 166 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

Stephen Johnston, Roberto Hegg, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2020 · 126 citations

Medicine, Oncology, Pharmacology +17

Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

Jens Huober, Eileen Holmes, José Baselga et al. · European Journal of Cancer · 2019 · 90 citations · Full text

Medicine, Oncology, Breast Oncology +12

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF‐1 suppression to octreotide LAR in healthy volunteers

Fredrik Tiberg, John G. Roberts, Camilla Cervin et al. · British Journal of Clinical Pharmacology · 2015 · 71 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14